181 related articles for article (PubMed ID: 36566100)
21. Grade Group Underestimation in Prostate Biopsy: Predictive Factors and Outcomes in Candidates for Active Surveillance.
Audenet F; Rozet F; Resche-Rigon M; Bernard R; Ingels A; Prapotnich D; Sanchez-Salas R; Galiano M; Barret E; Cathelineau X
Clin Genitourin Cancer; 2017 Dec; 15(6):e907-e913. PubMed ID: 28522288
[TBL] [Abstract][Full Text] [Related]
22. Risk of Biochemical Recurrence in Patients With Grade Group 1 Prostate Cancer With Extraprostatic Extension Treated With Radical Prostatectomy.
Rezaee ME; Pallauf M; Fletcher SA; Han M; Pavlovich CP; Cornelia Ding CK; Epstein JI; Allaf ME; Trock BJ; Singla N
J Urol; 2024 Mar; 211(3):407-414. PubMed ID: 38109699
[TBL] [Abstract][Full Text] [Related]
23. Pre-diagnosis urine exosomal RNA (ExoDx EPI score) is associated with post-prostatectomy pathology outcome.
Kretschmer A; Tutrone R; Alter J; Berg E; Fischer C; Kumar S; Torkler P; Tadigotla V; Donovan M; Sant G; Skog J; Noerholm M
World J Urol; 2022 Apr; 40(4):983-989. PubMed ID: 35084544
[TBL] [Abstract][Full Text] [Related]
24. Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.
Pierorazio PM; Ross AE; Lin BM; Epstein JI; Han M; Walsh PC; Partin AW; Pavlovich CP; Schaeffer EM
BJU Int; 2012 Oct; 110(8):1122-8. PubMed ID: 22373045
[TBL] [Abstract][Full Text] [Related]
25. The Impact of Delayed Radical Prostatectomy on Recurrence Outcomes After Initial Active Surveillance: Results from a Large Institutional Cohort.
Shee K; Cowan JE; Washington SL; Shinohara K; Nguyen HG; Cooperberg MR; Carroll PR
Eur Urol Oncol; 2023 Dec; ():. PubMed ID: 38057193
[TBL] [Abstract][Full Text] [Related]
26. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.
Bokhorst LP; Valdagni R; Rannikko A; Kakehi Y; Pickles T; Bangma CH; Roobol MJ;
Eur Urol; 2016 Dec; 70(6):954-960. PubMed ID: 27329565
[TBL] [Abstract][Full Text] [Related]
27. Pattern of Biopsy Gleason Grade Group 5 (4 + 5 vs 5 + 4 vs 5 + 5) Predicts Survival After Radical Prostatectomy or External Beam Radiation Therapy.
Wenzel M; Würnschimmel C; Chierigo F; Mori K; Tian Z; Terrone C; Shariat SF; Saad F; Tilki D; Graefen M; Mandel P; Roos FC; Chun FKH; Karakiewicz PI
Eur Urol Focus; 2022 May; 8(3):710-717. PubMed ID: 33933420
[TBL] [Abstract][Full Text] [Related]
28. Radical prostatectomy versus deferred treatment for localised prostate cancer.
Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic Accuracy and Prognostic Value of Serial Prostate Multiparametric Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer.
Chu CE; Cowan JE; Lonergan PE; Washington SL; Fasulo V; de la Calle CM; Shinohara K; Westphalen AC; Carroll PR
Eur Urol Oncol; 2022 Oct; 5(5):537-543. PubMed ID: 33483265
[TBL] [Abstract][Full Text] [Related]
30. Immediate versus delayed prostatectomy: Nationwide population-based study (.).
Loeb S; Folkvaljon Y; Robinson D; Makarov DV; Bratt O; Garmo H; Stattin P
Scand J Urol; 2016 Aug; 50(4):246-54. PubMed ID: 27067998
[TBL] [Abstract][Full Text] [Related]
31. Role of Metabolic Syndrome on Perioperative and Oncological Outcomes at Radical Prostatectomy in a Low-risk Prostate Cancer Cohort Potentially Eligible for Active Surveillance.
Colicchia M; Morlacco A; Rangel LJ; Carlson RE; Dal Moro F; Karnes RJ
Eur Urol Focus; 2019 May; 5(3):425-432. PubMed ID: 29306730
[TBL] [Abstract][Full Text] [Related]
32. Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies.
Martin DT; Ghabili K; Levi A; Humphrey PA; Sprenkle PC
Urology; 2019 Mar; 125():64-72. PubMed ID: 30552940
[TBL] [Abstract][Full Text] [Related]
33. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
[TBL] [Abstract][Full Text] [Related]
34. Adverse Pathologic Findings for Men Electing Immediate Radical Prostatectomy: Defining a Favorable Intermediate-Risk Group.
Patel HD; Tosoian JJ; Carter HB; Epstein JI
JAMA Oncol; 2018 Jan; 4(1):89-92. PubMed ID: 28715578
[TBL] [Abstract][Full Text] [Related]
35. Questioning the Status Quo: Should Gleason Grade Group 1 Prostate Cancer be Considered a "Negative Core" in Pre-Radical Prostatectomy Risk Nomograms? An International Multicenter Analysis.
Leong JY; Herrera-Caceres JO; Goldberg H; Tham E; Teplitsky S; Gomella LG; Trabulsi EJ; Lallas CD; Fleshner NE; Tilki D; Chandrasekar T
Urology; 2020 Mar; 137():102-107. PubMed ID: 31705947
[TBL] [Abstract][Full Text] [Related]
36. A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings.
Luzzago S; de Cobelli O; Cozzi G; Peveri G; Bagnardi V; Catellani M; Di Trapani E; Mistretta FA; Pricolo P; Conti A; Alessi S; Marvaso G; Ferro M; Matei DV; Renne G; Jereczek-Fossa BA; Petralia G; Musi G
BJU Int; 2020 Jul; 126(1):104-113. PubMed ID: 32150328
[TBL] [Abstract][Full Text] [Related]
37. Immediate versus delayed prostatectomy and the fate of patients who progress to a higher risk disease on active surveillance.
Mallya A; Senguttuvan-Karthikeyan V; Sivaraman A; Barret E; Galiano M; Cathala N; Mombet A; Prapotnich D; Sanchez-Salas R; Cathelineau X
Actas Urol Esp (Engl Ed); 2019; 43(6):324-330. PubMed ID: 30928176
[TBL] [Abstract][Full Text] [Related]
38. Untreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes.
Hussein AA; Welty CJ; Ameli N; Cowan JE; Leapman M; Porten SP; Shinohara K; Carroll PR
J Urol; 2015 Jul; 194(1):85-90. PubMed ID: 25623742
[TBL] [Abstract][Full Text] [Related]
39. Comparison of Biochemical Recurrence-Free Survival after Radical Prostatectomy Triggered by Grade Reclassification during Active Surveillance and in Men Newly Diagnosed with Similar Grade Disease.
Diniz CP; Landis P; Carter HB; Epstein JI; Mamawala M
J Urol; 2017 Sep; 198(3):608-613. PubMed ID: 28347771
[TBL] [Abstract][Full Text] [Related]
40. Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?
Deniffel D; Salinas E; Ientilucci M; Evans AJ; Fleshner N; Ghai S; Hamilton R; Roberts A; Toi A; van der Kwast T; Zlotta A; Finelli A; Haider MA; Perlis N
J Urol; 2020 Dec; 204(6):1187-1194. PubMed ID: 32496160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
